National Institute on Drug Abuse; Notice of Closed Meetings, 10911-10912 [2017-03081]

Download as PDF 10911 Federal Register / Vol. 82, No. 31 / Thursday, February 16, 2017 / Notices opportunity for public comment on proposed data collection projects, the Office of Extramural Research (OER), the National Institutes of Health (NIH) will publish periodic summaries of propose projects to be submitted to the Office of Management and Budget (OMB) for review and approval. DATES: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Dr. Sherry Mills, Director, Office of Extramural Programs, OER, NIH, 6705 Rockledge Drive, Suite 350, Bethesda, MD 20892, or call non-tollfree number (301) 435–2729, or Email your request, including your address to: OEPMailbox@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing. SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires: Written comments and/or suggestions from the public and affected agencies are invited forward with our initiatives to ensure success in accomplishing the NIH mission, input from partners and customers is essential. Quality management principles have been integrated into OER’s culture and these surveys will provide customer satisfaction input on various elements of OER’s business processes. The approximately 14 (10 quantitative and 4 qualitative) customer satisfaction surveys that will be conducted under this generic clearance will gather and measure customer and partner satisfaction with OER processes and operations. The data collected from these surveys will provide the feedback to track and gauge satisfaction with the NIH’s statutorily mandated operations and processes. OER/OD/NIH will present data and outcomes from these surveys to inform the NIH staff, officers, leadership, advisory committees, and other decision-making bodies as appropriate. Based on feedback from these stakeholders, OER/OD/NIH will formulate improvement plans and take action when necessary. OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 1911. to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Proposed Collection Title: Generic Clearance for Surveys of Customers and Partners of the Office of Extramural Research of the National Institutes of Health—Extension of 0925–0627— Office of the Director (OD), Office of Extramural Research (OER), Office of Extramural Programs (OEP), National Institutes of Health (NIH). Need and Use of Information Collection: OER develops, coordinates the implementation of, and evaluates NIH-wide policies and procedures for the award of extramural funds. To move ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Type of respondent Number of responses per respondent Average burden per response (in hours) Total annual burden hour Quantitative Survey Science professionals, applicants, reviewers, Institutional Officials ................ Adult Science Trainees .................................................................................... General Public ................................................................................................. 1,500 1,000 2,500 1 1 1 20/60 20/60 20/60 500 333 833 200 25 20 1 1 1 1 1 1 200 25 20 Qualitative Survey Science professionals, applicants, reviewers, Institutional Officials ................ Adult Science Trainees .................................................................................... General Public ................................................................................................. Dated: February 10, 2017. Lawrence A. Tabak, Deputy Director, National Institutes of Health. [FR Doc. 2017–03137 Filed 2–15–17; 8:45 am] National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings BILLING CODE 4140–01–P asabaliauskas on DSK3SPTVN1PROD with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., VerDate Sep<11>2014 19:05 Feb 15, 2017 Jkt 241001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIH Pathway to Independence Award (K99/R00). Date: February 27, 2017. Time: 12:30 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\16FEN1.SGM 16FEN1 asabaliauskas on DSK3SPTVN1PROD with NOTICES 10912 Federal Register / Vol. 82, No. 31 / Thursday, February 16, 2017 / Notices Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Susan O. McGuire, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, (301) 827–5817, mcguireso@mail.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; MultiSite Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01; R34). Date: March 1, 2017. Time: 1:00 p.m. to 3:15 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, (301) 827–5820, hiromi.ono@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01). Date: March 16, 2017. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. Contact Person: Susan O. McGuire, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, (301) 827–5817, mcguireso@mail.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Core Center of Excellence Grant Program (P30). Date: March 22, 2017. Time: 9:00 a.m. to 11:30 a.m. Agenda: To review and evaluate grant applications. Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy Chase, MD 20815. Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892–9550, 301–827–5819, gm145a@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Research ‘‘Center of Excellence’’ Grant Program (P50). Date: March 22–23, 2017. Time: 11:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. VerDate Sep<11>2014 19:05 Feb 15, 2017 Jkt 241001 Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy Chase, MD 20815. Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892–9550, 301–827–5819, gm145a@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Multisite Clinical Trials. Date: March 23, 2017. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Susan O. McGuire, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, (301) 827–5817, mcguireso@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: February 10, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–03081 Filed 2–15–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2017–0082] Certificate of Alternative Compliance for the TUG CLAYTON W MORAN Coast Guard, DHS. Notice. AGENCY: ACTION: The Coast Guard announces that a Certificate of Alternative Compliance (COAC) was issued for the TUG CLAYTON W MORAN. We are issuing this notice because its publication is required by statute. DATES: The Certificate of Alternative Compliance was issued on January 30th, 2017. FOR FURTHER INFORMATION CONTACT: For information or questions about this notice call or email Mr. Kevin Miller, First District Towing Vessel/Barge Safety Specialist, U.S. Coast Guard; telephone (617) 223–8272, email Kevin.L.Miller2@uscg.mil. SUPPLEMENTARY INFORMATION: The United States is signatory to the International Maritime Organization’s SUMMARY: PO 00000 Frm 00042 Fmt 4703 Sfmt 9990 International Regulations for Preventing Collisions at Sea, 1972 (72 COLREGS), as amended. The special construction or purpose of some vessels makes them unable to comply with the light, shape, and sound signal provisions of the 72 COLREGS. Under statutory law 1 and Coast Guard regulation,2 a vessel may instead meet alternative requirements and the vessel’s owner, builder, operator, or agent may apply for a COAC. For vessels of special construction, the cognizant Coast Guard District Office determines whether the vessel for which the COAC is sought complies as closely as possible with the 72 COLREGS, and decides whether to issue the COAC. Once issued, a COAC remains valid until information supplied in the COAC application or the COAC terms become inapplicable to the vessel. Under the governing statute 3 and regulation,4 the Coast Guard must publish notice of this action. The Commandant, U.S. Coast Guard, certifies that the TUG CLAYTON W MORAN is a vessel of special construction or purpose, and that, with respect to the position of the navigation and towing lights, it is not possible to comply fully with the requirements of the provisions enumerated in the 72 COLREGS, without interfering with the normal operation of the vessel. The Commandant further finds and certifies that the sidelights (13′ 5.25″ from the vessel’s side mounted on the pilot house) and stern/towing lights (3′ 5.75″ aft of frame 20 mounted on top of the pilot house) are in the closet possible compliance with the applicable provisions of the 72 COLREGS and that full compliance with the 72 COLREGS would not significantly enhance the safety of the vessel’s operation. This notice is issued under authority of 33 U.S.C. 1605(c) and 33 CFR. 81. Dated: February 6, 2017. Capt B.L. Black, Chief, Prevention Department, First District, U.S. Coast Guard. [FR Doc. 2017–03136 Filed 2–15–17; 8:45 am] BILLING CODE 9110–04–P 1 33 U.S.C. 1605(c). CFR 81.3. 3 33 U.S.C. 1605(c). 4 33 CFR 81.18. 2 33 E:\FR\FM\16FEN1.SGM 16FEN1

Agencies

[Federal Register Volume 82, Number 31 (Thursday, February 16, 2017)]
[Notices]
[Pages 10911-10912]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03081]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIH Pathway to Independence Award (K99/R00).
    Date: February 27, 2017.
    Time: 12:30 p.m. to 3:30 p.m.
    Agenda: To review and evaluate grant applications.

[[Page 10912]]

    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., 
Room 4245, Rockville, MD 20852, (301) 827-5817, 
mcguireso@mail.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Multi-Site Studies for System-Level Implementation 
of Substance Use Prevention and Treatment Services (R01; R34).
    Date: March 1, 2017.
    Time: 1:00 p.m. to 3:15 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Affairs, National Institute on Drug Abuse, 
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 
4238, MSC 9550, Bethesda, MD 20892, (301) 827-5820, 
hiromi.ono@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Mechanisms of Immune Activation and Inflammation: 
HIV Infection, ART, and Drugs of Abuse (R01).
    Date: March 16, 2017.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852.
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., 
Room 4245, Rockville, MD 20852, (301) 827-5817, 
mcguireso@mail.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA Core Center of Excellence Grant Program (P30).
    Date: March 22, 2017.
    Time: 9:00 a.m. to 11:30 a.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy 
Chase, MD 20815.
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, 301-827-5819, gm145a@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA Research ``Center of Excellence'' Grant Program 
(P50).
    Date: March 22-23, 2017.
    Time: 11:30 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy 
Chase, MD 20815.
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, 301-827-5819, gm145a@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Multi-site Clinical Trials.
    Date: March 23, 2017.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., 
Room 4245, Rockville, MD 20852, (301) 827-5817, 
mcguireso@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

     Dated: February 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-03081 Filed 2-15-17; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.